Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Michael Serenko"'
Autor:
Catharina G. Faber, Nadine Attal, Giuseppe Lauria, Robert H. Dworkin, Roy Freeman, Katherine T. Dawson, Helen Finnigan, Amirhossein Hajihosseini, Himanshu Naik, Michael Serenko, Christopher J. Morris, Mona Kotecha
Publikováno v:
EClinicalMedicine, Vol 59, Iss , Pp 101971- (2023)
Summary: Background: No pharmacological treatments are specifically indicated for painful small fibre neuropathy (SFN). CONVEY, a phase 2 enriched-enrolment study, evaluated the efficacy and safety of vixotrigine, a voltage- and use-dependent sodium
Externí odkaz:
https://doaj.org/article/98dd54c83e884b6a959fad1b27b55fcf
Autor:
Geoffrey A Block, Glenn M Chertow, John T Sullivan, Hongjie Deng, Omar Mather, Holly Tomlin, Michael Serenko
Publikováno v:
PLoS ONE, Vol 14, Iss 3, p e0213774 (2019)
BackgroundCalcimimetics have been shown to be effective and safe therapies for the treatment of secondary hyperparathyroidism (sHPT), a serious complication of disordered mineral metabolism associated with dialysis-dependent chronic kidney disease. E
Externí odkaz:
https://doaj.org/article/85ceb4e9c97e4c9d9d2d4bf9398b7c56
Autor:
Ganesh Raghu, Majd Mouded, Daniel C. Chambers, Fernando J. Martinez, Luca Richeldi, Lisa H. Lancaster, Mark J. Hamblin, Kevin F. Gibson, Ivan O. Rosas, Antje Prasse, Guolin Zhao, Michael Serenko, Natasha Novikov, Amy McCurley, Prashant Bansal, Christopher Stebbins, Million Arefayene, Stella Ibebunjo, Shelia M. Violette, Diana Gallagher, Jürgen Behr
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 206:1128-1139
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcb1ff0153c2c82a5cb358ce35be7158
https://doi.org/10.1164/rccm.202112-2824oc
https://doi.org/10.1164/rccm.202112-2824oc
Publikováno v:
Clinical Drug Investigation. 42:829-837
Vixotrigine is a voltage-dependent and use-dependent sodium channel blocker in development for the treatment of neuropathic pain. Metabolism of vixotrigine is primarily through glucuronidation, resulting in the major M13 metabolite. Two additional ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6e02c6e9fff419382fc686f333f59f3
https://doi.org/10.1007/s40261-022-01194-y
https://doi.org/10.1007/s40261-022-01194-y
Autor:
Raju Subramanian, Hongjie Deng, Michael Serenko, M. Benjamin Hock, Dohan Weeraratne, Benjamin M. Wu, Bethlyn Sloey, Mark A. Kroenke
Publikováno v:
Journal of Immunological Methods. 445:37-44
The immunogenicity risk assessment and bioanalytical strategy for novel therapeutics should account for both unique biophysical properties and potential consequences of immunogenicity. When assessing the immunogenicity risk of etelcalcetide, a peptid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::718313f79cd3460738bf11f15ada8c3a
https://doi.org/10.1016/j.jim.2017.03.005
https://doi.org/10.1016/j.jim.2017.03.005
Autor:
Yinzhong Chen, Michael Serenko, Atul R. Mahableshwarkar, Madhukar H. Trivedi, Paula L. Jacobsen
Publikováno v:
The Journal of Clinical Psychiatry. 76:583-591
Background This 8-week, randomized, double-blind, placebo-controlled study, conducted August 2010-May 2012 in the United States, evaluated the safety and efficacy of vortioxetine 10 mg and 15 mg in patients with major depressive disorder (MDD). The m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86c76c655fa7d03531b61567039be1bd
https://doi.org/10.4088/jcp.14m09337
https://doi.org/10.4088/jcp.14m09337
Autor:
Madhukar H. Trivedi, Yinzhong Chen, Michael Serenko, Paula L. Jacobsen, Atul R. Mahableshwarkar
Publikováno v:
Psychopharmacology
Rationale Vortioxetine has reduced depressive symptoms in adults with major depressive disorder (MDD) in multiple clinical trials. Objectives The aim of this study is to evaluate the efficacy, safety, and tolerability of vortioxetine 15 and 20 mg vs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::521016fb895d4802762c67b2e0fde552
https://doi.org/10.1007/s00213-014-3839-0
https://doi.org/10.1007/s00213-014-3839-0
Publikováno v:
International Clinical Psychopharmacology
Patients with major depressive disorder often experience relapse after responding to treatment; therefore, maintenance therapy with antidepressants is recommended for maintaining response or remission. This multicenter, open-label, flexible-dose, 52-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0ef7443af1ea216f2be196dc4958ed5
https://doi.org/10.1097/yic.0000000000000010
https://doi.org/10.1097/yic.0000000000000010
Publikováno v:
Human Psychopharmacology: Clinical and Experimental. 29:64-72
Background Vortioxetine is a recently approved multimodal antidepressant with anxiolytic properties in preclinical studies. Objective This double-blind, placebo-controlled study assessed the efficacy and tolerability of vortioxetine in subjects with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::237204deca11e919f57e487c87b83e7c
https://doi.org/10.1002/hup.2371
https://doi.org/10.1002/hup.2371
Autor:
Hongjie Deng, Holly Tomlin, Geoffrey A. Block, John T. Sullivan, Glenn M. Chertow, Michael Serenko, Omar Mather
Publikováno v:
PLoS ONE
PLoS ONE, Vol 14, Iss 3, p e0213774 (2019)
PLoS ONE, Vol 14, Iss 3, p e0213774 (2019)
BackgroundCalcimimetics have been shown to be effective and safe therapies for the treatment of secondary hyperparathyroidism (sHPT), a serious complication of disordered mineral metabolism associated with dialysis-dependent chronic kidney disease. E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14ce13f26128224e386bf4f7c977afe1
https://doi.org/10.1371/journal.pone.0213774
https://doi.org/10.1371/journal.pone.0213774